KR20190127779A - 약제학적 활성 지환족-치환된 피라졸로[1,5-a]피리미딘 유도체 - Google Patents

약제학적 활성 지환족-치환된 피라졸로[1,5-a]피리미딘 유도체 Download PDF

Info

Publication number
KR20190127779A
KR20190127779A KR1020197028833A KR20197028833A KR20190127779A KR 20190127779 A KR20190127779 A KR 20190127779A KR 1020197028833 A KR1020197028833 A KR 1020197028833A KR 20197028833 A KR20197028833 A KR 20197028833A KR 20190127779 A KR20190127779 A KR 20190127779A
Authority
KR
South Korea
Prior art keywords
methyl
formula
carboxylic acid
pyrazolo
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197028833A
Other languages
English (en)
Korean (ko)
Inventor
이스트반 보르자
빅토르 로만
자노스 엘스
주자 하다디
Original Assignee
리히터 게데온 닐트.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리히터 게데온 닐트. filed Critical 리히터 게데온 닐트.
Publication of KR20190127779A publication Critical patent/KR20190127779A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197028833A 2017-03-13 2018-03-12 약제학적 활성 지환족-치환된 피라졸로[1,5-a]피리미딘 유도체 Ceased KR20190127779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
HUP1700108 2017-03-13
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
KR20190127779A true KR20190127779A (ko) 2019-11-13

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197028833A Ceased KR20190127779A (ko) 2017-03-13 2018-03-12 약제학적 활성 지환족-치환된 피라졸로[1,5-a]피리미딘 유도체

Country Status (32)

Country Link
US (1) US11026946B2 (enExample)
EP (1) EP3596080B1 (enExample)
JP (1) JP7153662B2 (enExample)
KR (1) KR20190127779A (enExample)
CN (1) CN110431142A (enExample)
AR (1) AR111176A1 (enExample)
AU (1) AU2018235266B2 (enExample)
BR (1) BR112019018843A2 (enExample)
CA (1) CA3056185A1 (enExample)
CL (1) CL2019002601A1 (enExample)
CO (1) CO2019010120A2 (enExample)
CY (1) CY1124708T1 (enExample)
DK (1) DK3596080T3 (enExample)
EA (1) EA038756B1 (enExample)
EC (1) ECSP19072975A (enExample)
ES (1) ES2893824T3 (enExample)
GE (1) GEP20217256B (enExample)
HR (1) HRP20211850T1 (enExample)
HU (2) HU231058B1 (enExample)
IL (1) IL268923A (enExample)
LT (1) LT3596080T (enExample)
MX (1) MX2019011000A (enExample)
MY (1) MY195262A (enExample)
PE (1) PE20191646A1 (enExample)
PH (1) PH12019501968A1 (enExample)
PL (1) PL3596080T3 (enExample)
PT (1) PT3596080T (enExample)
RS (1) RS62533B1 (enExample)
SG (1) SG11201907864YA (enExample)
SI (1) SI3596080T1 (enExample)
UA (1) UA124783C2 (enExample)
WO (1) WO2018167630A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2021239558A1 (en) 2020-05-27 2021-12-02 Esteve Pharmaceuticals, S.A. Pyrazolo[1,5-a]pyrimidine derivatives having multimodal activity against pain
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508310A (pt) 2004-03-02 2007-07-24 Hoffmann La Roche derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR100753017B1 (ko) * 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-a]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
WO2009123986A1 (en) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
WO2016169995A1 (en) * 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Also Published As

Publication number Publication date
PE20191646A1 (es) 2019-11-07
HUP1700108A2 (en) 2018-09-28
US11026946B2 (en) 2021-06-08
IL268923A (en) 2019-10-31
CY1124708T1 (el) 2022-07-22
AR111176A1 (es) 2019-06-12
BR112019018843A2 (pt) 2020-04-14
AU2018235266B2 (en) 2021-09-30
EP3596080B1 (en) 2021-09-01
ECSP19072975A (es) 2019-11-30
HRP20211850T1 (hr) 2022-03-04
GEP20217256B (en) 2021-05-25
JP2020510041A (ja) 2020-04-02
HUE056562T2 (hu) 2022-02-28
PL3596080T3 (pl) 2022-01-31
JP7153662B2 (ja) 2022-10-14
SG11201907864YA (en) 2019-09-27
RS62533B1 (sr) 2021-11-30
ES2893824T3 (es) 2022-02-10
AU2018235266A1 (en) 2019-10-17
CN110431142A (zh) 2019-11-08
MX2019011000A (es) 2019-10-17
CO2019010120A2 (es) 2019-10-09
UA124783C2 (uk) 2021-11-17
WO2018167630A1 (en) 2018-09-20
HU231058B1 (hu) 2020-04-28
US20200129515A1 (en) 2020-04-30
SI3596080T1 (sl) 2022-01-31
EP3596080A1 (en) 2020-01-22
DK3596080T3 (da) 2021-11-15
EA201992127A1 (ru) 2020-02-06
CL2019002601A1 (es) 2020-01-24
MY195262A (en) 2023-01-11
LT3596080T (lt) 2021-11-25
PT3596080T (pt) 2021-10-22
PH12019501968A1 (en) 2020-06-29
EA038756B1 (ru) 2021-10-14
CA3056185A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
EP3596080B1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives
EP3596079B1 (en) Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives
CN102153562B (zh) 螺-吲哚酮化合物及其作为治疗剂的用途
KR101468285B1 (ko) 바소프레신 길항제로서의 아릴-/헤테로아릴-사이클로헥센일-테트라아자벤조〔e〕아줄렌
KR20100063087A (ko) 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
TWI907472B (zh) 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
JP2026514121A (ja) Nlrp3阻害剤としてのピラゾロピリミジン誘導体
US20180118728A1 (en) Novel pyridinium compounds
JP2026515688A (ja) Aak1阻害剤としての窒素複素環系化合物
EA049144B1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ ЗАМЕЩЕННЫЕ ПО ГЕТЕРОЦИКЛИЧЕСКОМУ ФРАГМЕНТУ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
OA19480A (en) Pharmacologically active alicyclicsubstituted pyrazolo [1,5-a] pyrimidine derivatives.
TW202341993A (zh) 作為血小板活化因子受體拮抗劑之環戊烷并噻吩甲醯胺衍生物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191001

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230309

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230623

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230309

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I